NDA 201444 · Hope Pharms
Nithiodote
Sodium Nitrite, Sodium Thiosulfate · Intravenous, Intravenous
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jan 13, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Jan 14, 2011
Approved uses
1
Original approval plus efficacy supplements
Registered trials
81
7 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LIFE THREATENING HYPOTENSION AND METHEMOGLOBIN FORMATION Sodium nitrite can cause serious adverse reactions and death in humans, even at doses less than twice the recommended therapeutic dose. Sodium nitrite causes hypotension and methemoglobin formation, which diminishes oxygen carrying capacity. Hypotension and methemoglobin formation can occur concurrently or separately. Because of these risks, sodium nitrite should be used to treat acute life-threatening cyanide poisoning and be used with caution in patients where the diagnosis of cyanide poisoning is uncertain . Patients should be closely monitored to ensure adequate perfusion and oxygenation during treatment with sodium nitrite. Alternative therapeutic approaches should be considered in patients known to have diminished oxygen or cardiovascular reserve (e.g. smoke inhalation victims, pre-existing anemia, cardiac or...
What it is approved for
From the label in effect Oct 6, 2025.
NITHIODOTE is indicated for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. When the diagnosis of cyanide poisoning is uncertain, carefully weigh the potentially life-threatening risks associated with NITHIODOTE against the potential benefits, especially if the patient is not in extremis. NITHIODOTE, an antidote, is indicated for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. ( 1 ) Use with caution if the diagnosis of cyanide poisoning is uncertain. ( 1 )
Mechanism: Cyanide is an extremely toxic poison. In the absence of rapid and adequate treatment, exposure to a high dose of cyanide can result in death within minutes due to the inhibition of cytochrome oxidase resulting in arrest of cellular respiration. Specifically, cyanide binds rapidly with cytochrome a3, a component of the cytochrome c oxidase complex in mitochondria. Inhibition of cytochrome a3 prevents the cell from using oxygen and forces anaerobic metabolism, resulting in lactate production, cellular hypoxia and metabolic acidosis. In massive acute cyanide poisoning, the mechanism of toxicity...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 14, 2011 Original approval · Type 5 - New Formulation or New Manufacturer · priority review OrphanReviewLetterLabel
1 products under this application
- NITHIODOTE · SODIUM NITRITE 300MG/10ML(30MG/ML),N/A; SODIUM THIOSULFATE N/A,12.5GM/50ML(250MG/ML) · SOLUTION, SOLUTION, INTRAVENOUS, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nitrite" as an intervention, any sponsor and status, largest first.
- Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac ArrestPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT03452917 · 1,502 participants · Start Feb 8, 2018 · Primary completion Dec 31, 2019
Drug: Placebo; sodium nitrite 45 mg and 1 more · For: Out-Of-Hospital Cardiac Arrest
Sites: Seattle, Washington
- The Use of Inorganic Nitrate for the Prevention of Contrast-induced NephropathyPivotal-lookingCompleted
Barts & The London NHS TrustAcademic, hospital or other
NCT03627130 · 640 participants · Start Nov 29, 2018 · Primary completion May 30, 2022
Drug: Potassium Nitrate; Potassium Chloride · For: Contrast-induced Nephropathy; Acute Kidney Injury; Acute Coronary Syndrome
Sites: London, United Kingdom
- A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital WartsPivotal-lookingCompleted
University of AberdeenAcademic, hospital or other
NCT02015260 · 299 participants · Start Sep 2001 · Primary completion May 2003
Drug: Topical NO; Placebo · For: Anogenital Warts; Condylomata Acuminata
- Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19Pivotal-lookingTerminated
University of BirminghamAcademic, hospital or other
NCT04386070 · 281 participants · Start May 16, 2022 · Primary completion Jun 30, 2023
Drug: RESP301 · For: Pulmonary Complications in Surgical Patients; COVID; Severe Acute Respiratory Syndrome
Sites: Gwagwalada, Nigeria; Lagos, Nigeria; Nnewi, Nigeria · 9 sites in all
- Nitrites in Acute Myocardial InfarctionPivotal-lookingCompleted
University of AberdeenAcademic, hospital or other
NCT01388504 · 200 participants · Start Jul 2011 · Primary completion Jan 2014
Drug: sodium nitrite · For: Acute ST Elevation Myocardial Infarction
Sites: Aberdeen, United Kingdom; Brighton, United Kingdom; London, United Kingdom
- Lactobacillus Reuteri for Treatment of Uncomplicated UTI in Pregnant WomenPivotal-lookingCompleted
Innovacion y Desarrollo de Estrategias en SaludAcademic, hospital or other
NCT03362697 · 150 participants · Start Dec 15, 2017 · Primary completion Dec 30, 2018
Drug: Antibiotics · For: Urinary Tract Infection in Pregnancy
Sites: Mexico City, Mexico
University of Colorado, DenverAcademic, hospital or other
NCT02463357 · 148 participants · Start Aug 2015 · Primary completion Sep 2016
Drug: Nifedipine extended release; Methazolamide and 3 more · For: Mountain Sickness
Sites: Alma, Michigan
- Evaluation of Ureteral Patency in the Post-indigo Carmine EraPivotal-lookingCompleted
Columbia UniversityAcademic, hospital or other
NCT02677623 · 140 participants · Start Mar 2015 · Primary completion Aug 2016
Drug: Pyridium; Sodium Fluorescein and 1 more · For: Ureteral Patency
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Beetroot juice and exercise: pharmacodynamic and dose-response relationships.
Wylie LJ, Kelly J, Bailey SJ, et al. · J Appl Physiol (1985) 2013 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Beet the Best?
Woessner M, VanBruggen MD, Pieper CF, et al. · Circ Res 2018 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Beetroot Juice Supplementation Improves High-Intensity Intermittent Type Exercise Performance in Trained Soccer Players.
Nyakayiru J, Jonvik KL, Trommelen J, et al. · Nutrients 2017 · Randomized Controlled Trial
- Accuracy of leukocyte esterase and nitrite tests for diagnosing bacteriuria in older adults: a systematic review and meta-analysis.
Moragas A, Monfà R, García-Sangenís A, et al. · Clin Microbiol Infect 2026 · Meta-Analysis, Systematic Review
- Beneficial Effect of Sodium Nitrite on EEG Ischaemic Markers in Patients with Subarachnoid Haemorrhage.
Luettich A, Franko E, Spronk DB, et al. · Transl Stroke Res 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Interventions for cutaneous molluscum contagiosum.
van der Wouden JC, van der Sande R, van Suijlekom-Smit LW, et al. · Cochrane Database Syst Rev 2009 · Meta-Analysis, Systematic Review
Sponsor: Hope Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.